Although different research groups have resolved the crystal structures of Lp-PLA2, both alone and when bound with other inhibitors, medicines that can target Lp-PLA2 are still lacking for the treatment of ischemic stroke and other diseases associated with the elevations of Lp-PLA2 activity or mass. This evidence concerns the gene PLA2G7 and ischemic stroke.